Bansback N - Search Results

1

Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.

McClean AR, Cheng L, Bansback N, Clement F, Tadrous M, Harrison M, Law MR. McClean AR, et al. Among authors: bansback n. Arthritis Care Res (Hoboken). 2023 Sep;75(9):2011-2021. doi: 10.1002/acr.25099. Epub 2023 Mar 4. Arthritis Care Res (Hoboken). 2023. PMID: 36752358

2

Health state utility values: a description of their development and application for rheumatic diseases.

Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra C, Symmons D, Anis A. Bansback N, et al. Arthritis Rheum. 2008 Jul 15;59(7):1018-26. doi: 10.1002/art.23813. Arthritis Rheum. 2008. PMID: 18576311 Free article. Review. No abstract available.

3

How important is mode of administration in treatments for rheumatic diseases and related conditions?

Bansback N, Trenaman L, Harrison M. Bansback N, et al. Curr Rheumatol Rep. 2015 Jun;17(6):514. doi: 10.1007/s11926-015-0514-3. Curr Rheumatol Rep. 2015. PMID: 25903666 Review.

4

Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment.

Harrison M, Marra C, Shojania K, Bansback N. Harrison M, et al. Among authors: bansback n. Rheumatology (Oxford). 2015 Oct;54(10):1816-25. doi: 10.1093/rheumatology/kev113. Epub 2015 May 18. Rheumatology (Oxford). 2015. PMID: 25989956

5

Does Introducing Imprecision around Probabilities for Benefit and Harm Influence the Way People Value Treatments?

Bansback N, Harrison M, Marra C. Bansback N, et al. Med Decis Making. 2016 May;36(4):490-502. doi: 10.1177/0272989X15600708. Epub 2015 Aug 24. Med Decis Making. 2016. PMID: 26304064 Clinical Trial.

6

Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment.

Penton H, Hiligsmann M, Harrison M, Reginster JY, Boonen A, Bansback N. Penton H, et al. Among authors: bansback n. Osteoporos Int. 2016 Sep;27(9):2697-2707. doi: 10.1007/s00198-016-3596-5. Epub 2016 May 7. Osteoporos Int. 2016. PMID: 27155885

7

Preferences for 'New' Treatments Diminish in the Face of Ambiguity.

Harrison M, Marra CA, Bansback N. Harrison M, et al. Among authors: bansback n. Health Econ. 2017 Jun;26(6):743-752. doi: 10.1002/hec.3353. Epub 2016 May 12. Health Econ. 2017. PMID: 27174417

8

Attitude to health risk in the Canadian population: a cross-sectional survey.

Bansback N, Harrison M, Sadatsafavi M, Stiggelbout A, Whitehurst DG. Bansback N, et al. CMAJ Open. 2016 Jun 3;4(2):E284-91. doi: 10.9778/cmajo.20150071. eCollection 2016 Apr-Jun. CMAJ Open. 2016. PMID: 27398375 Free PMC article.

9

Communicating Uncertainty in Benefits and Harms: A Review of Patient Decision Support Interventions.

Bansback N, Bell M, Spooner L, Pompeo A, Han PKJ, Harrison M. Bansback N, et al. Patient. 2017 Jun;10(3):311-319. doi: 10.1007/s40271-016-0210-z. Patient. 2017. PMID: 27905072 Review.

10

Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments.

Harrison M, Milbers K, Hudson M, Bansback N. Harrison M, et al. Among authors: bansback n. BMJ Open. 2017 May 17;7(5):e014719. doi: 10.1136/bmjopen-2016-014719. BMJ Open. 2017. PMID: 28515194 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Search Page

Filters